ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT NOVEMBER 2024
Zinzino group revenue increased with a total of 26 %, compared with the previous year.
The revenue in November for Zinzino's sales markets increased by 26 % and amounted to SEK 252.7 (201.1) million. Faun Pharma's external sales increased by 33 % and amounted to SEK 10.0 (7.5) million. Overall, the Group increased revenues by 26 % to SEK 262.7 (208.6) million compared with the previous year.
Accumulated revenue for January – November 2024 increased by 21 % to SEK 1955.9 (1611.0) million.
Revenues were distributed as follows:
Regions,MSEK | 24-Nov | 23-Nov | Change | YTD 2024 | YTD 2023 | Change |
The Nordics | 29.0 | 27.9 | 4% | 272.0 | 273.6 | -1% |
Central Europe | 70.9 | 49.9 | 42% | 519.2 | 394.5 | 32% |
East Europe | 52.4 | 49.8 | 5% | 366.8 | 362.3 | 1% |
South & West Europe | 45.1 | 35.5 | 27% | 346.7 | 242.0 | 43% |
The Baltics | 16.2 | 13.0 | 25% | 95.7 | 89.8 | 7% |
North America | 25.9 | 15.2 | 70% | 179.2 | 100.2 | 79% |
Asia-Pacific | 10.8 | 8.3 | 30% | 64.2 | 51.3 | 25% |
Africa | 2.4 | 1.5 | 60% | 15.0 | 12.3 | 22% |
Zinzino | 252.7 | 201.1 | 26% | 1858.8 | 1526.0 | 22% |
Faun Pharma | 10.0 | 7.5 | 33% | 97.1 | 85.0 | 14% |
Zinzino Group | 262.7 | 208.6 | 26% | 1955.9 | 1611.0 | 21% |
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, www.zinzino.com
Pictures for publication free of charge: marketing@zinzino.com
Certified Adviser: Carnegie Investment Bank AB (publ.)
Zinzino is a global direct sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their scientifically proven nutritional supplements are available on more than 100 markets across the world. Zinzino owns the Swiss, biotech skincare brand HANZZ+HEIDII, as well as the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Europe, Asia and Australia.